Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Mar 15, 2018 (9 years ago)

buPROPion HCl Extended-Release Tablets (Bupropion Hydrochloride)

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Dissolution Specifications; during stability testing

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

buPROPion HCl Extended-Release Tablets, USP (SR), 100 mg, 60 count bottles, Rx Only, Manufactured for: Cipla USA Inc. 1560 Sawgrass Corporate Parkway Suite 130 Sunrise, FL 33323, Manufactured by: InvaGen Pharmaceuticals, Inc. (a subsidiary of Cipla Ltd.) Hauppauge, NY 11788 --- NDC 69097-877-03

Affected NDC 69097-0877-03

Compare with the code on your package — it is the most precise check available.

Drug: Bupropion Category: Mental Health Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Bupropion Hydrochloride (sr)
Bupropion Hydrochloride
NDC 69097-0877
100 mg/1 Tablet, Extended Release
Oral
Cipla USA Inc., Rx
Recalling firm
InvaGen Pharmaceuticals, Inc.
NDC code
69097-877-03
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0618-2018 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Bupropion recalls

See all

Other recalls by InvaGen Pharmaceuticals, Inc.

All 2018 recalls
Class III · Low risk

Gabapentin Tablets USP

Failed Impurities/Degradation Specifications; failure of Impurity A test at the 12-month long-term stability testing.

Terminated Impurity / degradation InvaGen Pharmaceuticals, Inc. NDC 76282-405-05 D-1272-2020